Chronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling
Teja Devarakonda(Virginia Commonwealth University), Fadi N. Salloum(Virginia Commonwealth University)
Cited by 8
Related Papers
B7‐33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction–Related Adverse Cardiac Remodeling in Mice
|Journal of the American Heart Association|2020|20